AFP and hepatocellular carcinoma: In enrolled HCC patients, 58 of 64 patients (90.6%) showed detectable level of CNVs and TFx in cfDNA before initiating TACE treatment, with mean TFx value of 0.159 (range: 0.006–0.581), while only 78.1% of them showed positive level of AFP (> 20 ng·mL−1; Fig. S1C).